Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Cipla hopes to...

    Cipla hopes to generate sustainable top-line growth in FY18

    Written by Ruby Khatun Khatun Published On 2017-08-13T09:20:15+05:30  |  Updated On 13 Aug 2017 9:20 AM IST
    Cipla hopes to generate sustainable top-line growth in FY18

    Mumbai: Cipla on Friday said even as the industry faces several hurdles, the government's new drug policy will boost the pharma sector and the company hopes to generate sustainable and profitable top-line growth in FY18.


    "The industry saw a slow growth rate in the recent past mostly due to the government policies and control measures.


    "The industry also witnessed increasing pressure on the global pharmaceutical industry - regulatory and compliance issues are getting more demanding, intellectual property rights increasingly have become more complex and pricing pressures are intensifying," Cipla chairman Y K Hamied told shareholders here.


    Addressing the company's 81st annual general meeting, Hamied said though the industry is facing several hurdles, the new drug policy is expected to be positive for the sector.


    "A new national pharmaceutical policy is in the making and we hope it will positively encourage the industry in the present and future.


    "The Drugs and Cosmetics Act and Rules is currently undergoing change to ensure quality, safety and efficacy of drugs. The government is also set to launch a workable clinical trials policy that will promise greater transparency and better checks for patients safety," he said.


    A mandatory code is expected to replace the current voluntary Uniform Code for Pharmaceutical Marketing Practices (UCPMP) for increased adherence and governance. A separate ministry for pharmaceuticals and medical devices has been contemplated to establish efficiency, streamline regulatory approval processes and improve transparency and profitability, Hamied said.


    "Our biggest imperative in FY18 will be to generate sustainable and profitable top-line growth. We will work towards bolstering our leadership position in India, South Africa and key emerging markets.


    "In the US, we are eyeing over 20 ANDA filings, strengthening the execution of key launches and building our specialty focus in respiratory and CNS," said Cipla managing director and CEO Umang Vohra.


    The company managed to maintain a suitable growth despite a highly competitive environment due its investment in R&D. The company invested 7.6 per cent of its total revenue and remained leaders conducting effective R&D in the domestic pharmaceutical landscape, he said.


    The company filed three products in Q1FY18 and filing is expected to intensity in the remaining part of the fiscal with a target to file 25 ANDAs in the full year.


    "We have filed many patents in India and internationally and we are confident the overall result of our initiatives will be evident in the coming years," Vohra added.


    During FY17, the company's domestic business grew by 10 per cent despite pricing challenges and the impact of demonetisation. The company had successfully integrated its two recent acquisitions, InvaGen and Exelan into its global mainstream operations.


    "Recently, Cipla USA was ranked 9th highest in prescriptions among all the US generic companies. Besides, we are among the leaders in South Africa and also in several smaller countries, such as Uganda, Sri Lanka, and Mauritius, among others and we will continue to serve multiple markets effectively throughout the world," the chairman said.

    CiplaDemonetisationgenerategovernment policiesgrowthhopesIntellectual Property RightsMedical Devicespharma sectorpricing pressuressustainabletop-lineUmang VohraY K Hamied
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok